Endometriosis New Zealand warmly welcomes Pharmac – Te Pātaka Whaioranga’s decision to fund oestradiol gel a new option for hormone treatment, with hopes to benefit thousands of New Zealanders. We see this outcome as a positive step in addressing gender equity in healthcare, where access to essential treatments has historically been limited.
Endometriosis New Zealand is encouraged by Pharmac’s decision, seeing it as a reflection of an ongoing commitment to improving women’s health and ensuring equitable access to essential treatments. We hope this is one of many positive developments in healthcare and that we continue to see decisions made that will uplift the health and well-being of individuals affected by endometriosis.
“Endometriosis New Zealand looks forward to providing consultation to Pharmac in the coming months to ensure the priorities of our endometriosis community in Aotearoa are heard and considered in future funding decisions.”– Tanya Cooke, Endometriosis New Zealand CEO.
For more information and Pharmac’s full media release, visit the link below: